8-K ·Filed Apr 22, 2026
8-K context-dependent: Items 8.01
Actionable Insight • Neutral
Monitor upcoming ASCO presentations for any new efficacy or safety data that could influence clinical adoption, but expect no immediate financial impact from this announcement.
Final — all horizons settled through T+60d
FENC ▲ +48.65% at T+60d
NEUTRAL call +48.65% · α vs SPY +43.63% · entry $6.66 → $9.90
T+1d
+2.70%
call +2.70% · α +1.92%
$6.84
settled 6mo ago
T+5d
-6.01%
call -6.01% · α -7.48%
$6.26
settled 6mo ago
T+20d
+46.40%
call +46.40% · α +41.76%
$9.75
settled 5mo ago
T+60d
+48.65%
call +48.65% · α +43.63%
$9.90
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
Fennec Pharmaceuticals announced that four clinical studies on PEDMARK were accepted for presentation at the 2026 ASCO Annual Meeting, highlighting ongoing clinical interest in the drug's use for preventing cisplatin-induced hearing loss. This is a routine scientific update with no financial impact.
Key Facts
- Four abstracts on PEDMARK accepted for ASCO 2026 Annual Meeting
- Presentations include data from pediatric, adult, and real-world settings
- PEDMARK is FDA-approved to reduce ototoxicity risk in pediatric patients receiving cisplatin chemotherapy
Financial Impact
None
Risk Factors
- Clinical trial results presented at ASCO may not confirm prior findings
- Limited commercial uptake if clinical adoption remains slow
Market Snapshot
Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-046804 |
| Document: fencf-20260422xex99d1.htm | 0001104659-26-046804 |
| Document: 0001104659-26-046804-index-headers.html | 0001104659-26-046804 |
| Document: 0001104659-26-046804-index.html | 0001104659-26-046804 |
| Document: 0001104659-26-046804.txt | 0001104659-26-046804 |
18 reports for FENC
100% Hit rate @ T+60 Went positive at some point 4 of 5 best @ T+60▲ +50.50%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | SC 13G/A | $10.27 | awaiting T+60 | — | $10.30 (+0.29%) |
Aug 31, 2026 8w ago | Insider Cluster | $12.03 | awaiting T+60 | — | $10.30 (−14.38%) |
Aug 31, 2026 8w ago | Insider Cluster | $12.03 | awaiting T+60 | — | $10.30 (−14.38%) |
Aug 11, 2026 11w ago | Press Release | $12.78 | awaiting T+60 | — | $10.30 (−19.41%) |
Jun 15, 2026 19w ago | Press Release | $9.19 $11.65 | ▲ +26.77% | ▲ +25.77% | $10.30 (+12.08%) |
May 22, 2026 22w ago | 8-K | $9.89 $11.87 | ▲ +20.02% | ▲ +17.30% | $10.30 (+4.15%) |
May 18, 2026 23w ago | 8-K | $9.76 $12.06 | ▲ +23.57% | ▲ +17.28% | $10.30 (+5.53%) |
May 14, 2026 23w ago | Press Release | $9.24 $10.94 | ▲ +18.40% | ▲ +14.81% | $10.30 (+11.47%) |
May 7, 2026 24w ago | Press Release | $6.90 $9.59 | ▲ +38.99% | ▲ +35.15% | $10.30 (+49.28%) |
Apr 28, 2026 25w ago | 8-K | $6.26 $9.99 | ▲ +59.58% | ▲ +55.47% | $10.30 (+64.54%) |
Showing 10 of 18
US Market Status
Market Open — Closes in 5h 19m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers